HALOPERIDOL IN THE TREATMENT OF 120 PSYCHOTIC PATIENTS
Abstract
The results of treatment with haloperidal at the Towers Hospital, Leicester, England, confirm those of Continental workers in the same field. We agree with their opinions (3, 4, 11, 12), that haloperidol is without any doubt a major advance in the management and treatment of paranoid-type schizophrenics as well as recent mania.
Its clinical usefulness and importance are dependent upon: 1. The fact that it is a long acting drug and needs to be administered only once a day; 2. The fact that no serious toxic reactions have been reported and frequent laboratory referrals can be avoided; 3. The combination of minimal soporific effects and maximum tranquilisation so that the patient is alert and yet his management presents no nursing difficulties; 4. Helping to cut expenses of inpatient treatment due to quick recovery and duration of hospitalisation; and 5. Its reaction on the disturbed patient eliminating the need for locked wards or locked rooms.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
